View Older Stories View More Recent Stories

Dec 13, 2021 01:00AM Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
Dec 13, 2021 12:59AM Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Dec 11, 2021 12:00PM New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
Dec 8, 2021 05:31PM Regeneron (REGN) Announces Publication of Positive Phase 3 Data of Dupixent in Children with Moderate-to-Severe Asthma
Dec 8, 2021 05:30PM New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
Dec 8, 2021 05:29PM Regeneron (REGN) Announces NEJM Publishes Positive Phase 3 Dupixent Results in Children with Moderate-to-severe Asthma
Dec 8, 2021 05:29PM New England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Results in Children with Moderate-to-severe Asthma
Dec 3, 2021 10:00AM Regeneron to Participate in H.C. Wainwright & Co. Virtual Event
Nov 16, 2021 04:15PM Regeneron Announces Investor Conference Presentations
Nov 15, 2021 07:00AM Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year
Nov 12, 2021 04:12PM Regeneron (REGN) Announces $3 Billion Share Repurchase Program
Nov 12, 2021 04:11PM Regeneron Announces $3 Billion Share Repurchase Program
Nov 12, 2021 10:26AM Regeneron (REGN) Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
Nov 12, 2021 10:20AM Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-19
Nov 11, 2021 11:05AM CHMP Recommends EU Approves Regeneron (REGN) Antibody Cocktail for Treatment and Prevention of COVID-19
Nov 11, 2021 11:03AM CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-19
Nov 8, 2021 08:50AM Pre-Open Stock Movers 11/08: (AUTL) (TTD) (BLNK) Higher; (EHTH) (BLUE) (TSLA) Lower (more...)
Nov 8, 2021 07:01AM Regeneron (REGN) Announces New Phase 3 Analyses Show That Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Nov 8, 2021 07:00AM New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Nov 4, 2021 10:00AM Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders
Nov 4, 2021 06:30AM Regeneron Reports Third Quarter 2021 Financial and Operating Results
Oct 25, 2021 05:32AM Regeneron (REGN) and Sanofi (SNY) Report Second Dupixent Phase 3 Trial Achieves Primary Endpoints Demonstrating Significant Disease Improvements
Oct 25, 2021 01:00AM Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
Oct 25, 2021 12:59AM Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease
Oct 22, 2021 05:50AM Regeneron's (REGN) Dupixent Significantly Reduces Itch and Skin Lesions in Phase 3 trial for prurigo nodularis
Oct 22, 2021 01:00AM Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
Oct 22, 2021 12:59AM Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease
Oct 20, 2021 05:30PM Regeneron (REGN) Announces FDA Expands Approval of Dupixent to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Oct 20, 2021 05:30PM FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
Oct 20, 2021 05:29PM FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Oct 14, 2021 07:22AM FDA Accepts Regeneron's (REGN) REGEN-COV for Priority Review for Treatment and Prophylaxis of COVID-19
Oct 14, 2021 07:21AM FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
Oct 11, 2021 04:15PM Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021
Sep 30, 2021 01:00AM New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19
Sep 29, 2021 05:01PM Regeneron (REGN) Announces NEJM Publishes Positive Phase 3 Trial Results for REGEN-COV to Treat COVID-19
Sep 29, 2021 05:00PM New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Sep 28, 2021 07:02AM Regeneron (REGN) Announces FDA Accepts Libtayo for Priority Review for Advanced Cervical Cancer
Sep 28, 2021 07:00AM FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer
Sep 21, 2021 05:49AM Regeneron (REGN) and Sanofi (SNY) to Present New Dupixent® Data for Dermatitis in Children at WCPD and EADV
Sep 21, 2021 01:00AM New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
Sep 21, 2021 12:59AM New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV
Sep 19, 2021 06:16PM Regeneron's (REGN) Phase 3 Trial of Libtayo and Chemotherapy as First-line Treatment Met Primary and Secondary Endpoints
Sep 19, 2021 11:30AM ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Sep 19, 2021 11:30AM ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC
Sep 14, 2021 05:36PM Regeneron (REGN) Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV Antibody Cocktail
Sep 14, 2021 05:33PM Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail
Sep 8, 2021 04:05PM Regeneron Announces Investor Conference Presentations
Aug 30, 2021 01:00AM Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in ch
Aug 30, 2021 12:59AM Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Ch
Aug 24, 2021 07:04AM Regeneron (REGN) Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration
View More Recent Stories View Older Stories